Cypress Capital’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
Other funds holding GILD
LMFP
CIM
CGH
CNB
AP
COPPSERS
Cypress Capital's GILD Position: Q2 2026 in Review
Cypress Capital increased its Gilead Sciences (GILD) stake by 3.4% in Q2 2026, buying an estimated $9.88K and bringing the position to 2,254 shares worth $285K. The position accounts for 0.08% of the portfolio, ranked #87.
Cypress Capital first reported a position in GILD in Q4 2018 and has held it in 16 quarters since. The position peaked at $1.74M in Q2 2020. 425 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Cypress Capital held 2,254 shares of Gilead Sciences worth $285K as of Q2 2026.
- Cypress Capital bought 75 Gilead Sciences shares in Q2 2026, an estimated $9.88K.
- Gilead Sciences made up 0.08% of Cypress Capital's portfolio in Q2 2026, its #87 holding.
- Cypress Capital first reported a position in Gilead Sciences in Q4 2018 and has held it in 16 quarters since.
- Cypress Capital's Gilead Sciences position peaked at $1.74M in Q2 2020.
- 425 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Cypress Capital's 13F filing for Q2 2026, filed 17 Jul 2026.